Protocolnummer: CA045-001

A phase 3, randomized, open-label study of NKTR-214 (gesloten voor inclusie)

A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in particpants with previously untreated unresectable or metastatic melanoma

Doel van het onderzoek

To compare ORR, PFS and OS of NKTR-214 combined with nivolumab and that of nivolumab monotherapy in participants with previously untreated unresectable or metastatic melanoma

Behandeling

nivolumab + NKTR vs nivolumab alleen (1:1 randomisatie)

Belangrijkste in/exclusiecriteria

nivolumab + NKTR vs nivolumab alleen (1:1 randomisatie)

Contactpersoon

Karijn Suijkerbuijk en Annemarleen Kamphuis